BioAge Labs Overview of the Healthcare Conference
BioAge Labs, Inc. (NASDAQ: BIOA), an innovative clinical-stage biotechnology company, is gearing up for a momentous occasion. The company specializes in developing therapeutic products aimed at addressing metabolic diseases through the unique lens of human aging. Recently, BioAge announced its participation in the Piper Sandler 37th Annual Healthcare Conference.
Key Details of the Presentation
Scheduled for December, the conference takes place from the 2nd to the 4th. Kristen Fortney, PhD, the company's CEO, along with Dov Goldstein, MD, CFO, will be actively participating in discussions. They will feature in a live fireside chat on December 4th between 1:30 PM and 1:55 PM ET. This session aims to provide insights into BioAge's innovative research and developments.
What to Expect from BioAge Labs
During the presentation at the conference, BioAge plans to share critical updates on its lead product candidate, BGE-102, designed to tackle obesity and cardiovascular risks. This orally administered small-molecule NLRP3 inhibitor aims to bring forward new therapeutic options for individuals grappling with metabolic diseases.
The Phase 1 Trials
The company is currently engaged in a Phase 1 study of BGE-102, with initial Single Ascending Dose (SAD) results expected before the year concludes. The ongoing trials will provide valuable insights into the drug's efficacy, which could pave the way for further development and potential market introduction.
BioAge's Commitment to Innovation
BioAge's innovative approach is not limited to BGE-102. The company is also developing long-acting injectable and oral small molecule APJ agonists, further expanding its portfolio of therapeutic candidates for metabolic diseases. These initiatives reflect BioAge's commitment to addressing critical medical needs through the application of advanced research methodologies derived from insights into human longevity.
Understanding the Science of Aging
The fundamental objective of BioAge is to leverage human aging biology to unveil new avenues for therapy. The proprietary discovery platform built by BioAge encompasses insights from longevity research, which could play a crucial role in shaping future developments in the biotechnology sphere. This foundation enables BioAge to address the crucial pathways that foster improved metabolic health.
Contacting BioAge Labs
For more information, stakeholders or interested parties can reach out to BioAge Labs through various communication channels. PR inquiries can be directed to Chris Patil via email. For investor-related questions, Dov Goldstein is available for contact, and those interested in potential partnerships are encouraged to reach out through their dedicated email as well. BioAge also maintains an informative website that offers easy access to their investor relations and latest updates.
Frequently Asked Questions
What is the primary focus of BioAge Labs?
BioAge Labs focuses on developing therapeutic candidates aimed at treating metabolic diseases while targeting the biology of human aging.
When will BioAge Labs present at the Piper Sandler Conference?
BioAge Labs will present at the Piper Sandler 37th Annual Healthcare Conference from December 2-4.
Who from BioAge Labs will be presenting?
Kirsten Fortney, PhD, and Dov Goldstein, MD, will represent BioAge during the conference.
What is BGE-102?
BGE-102 is BioAge's lead product candidate, a small-molecule NLRP3 inhibitor aimed at addressing obesity and cardiovascular risk factors.
How can I contact BioAge Labs for more information?
You can reach BioAge Labs via their official website or through the specific emails provided for PR, investor relations, and partnerships.
